Nilotinib (AMN-107)

For research use only. Not for use in humans.

製品コードS1033

Nilotinib (AMN-107)化学構造

分子量(MW):529.52

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells. Nilotinib induces autophagy through AMPK activition.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 17100 あり
JPY 13600 あり
JPY 36800 あり
JPY 80000 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(80)

製品安全説明書

Bcr-Abl阻害剤の選択性比較

生物活性

製品説明 Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells. Nilotinib induces autophagy through AMPK activition.
特性 A selective inhibitor of native and mutant Bcr-Abl.
ターゲット
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
体外試験

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M3P2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvITWM2OD1yLkCwNFE1PCEQvF2= NEHhNYNUSU6JRWK=
KU812 NWXnbGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f1W2lEPTB;MD6wNFI1QCEQvF2= M4jHbnNCVkeHUh?=
EM-2 NEKwRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjwTo42UUN3ME2wMlAxPDFizszN NV:4O5hQW0GQR1XS
LAMA-84 M3jEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOwTWM2OD1yLkCwOFkh|ryP MUfTRW5ITVJ?
MEG-01 NXT0VplHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEC4Nlgh|ryP MmG2V2FPT0WU
BV-173 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D0VWlEPTB;MD6wNVA5QSEQvF2= MU\TRW5ITVJ?
KASUMI-1 NYf4VlM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j4TmlEPTB;MD6wNlQyOyEQvF2= MmfqV2FPT0WU
NB7 NVHOR4xxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfJTWM2OD1yLkGzOFM6KM7:TR?= NYLmfllTW0GQR1XS
BHT-101 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TSNWlEPTB;MD62OFI3OyEQvF2= M3uyPHNCVkeHUh?=
CGTH-W-1 M4TRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwNkS4O{DPxE1? NYm5XpBxW0GQR1XS
HMV-II NUj6SmRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TLV2lEPTB;MD63OFg4PCEQvF2= MoPZV2FPT0WU
NKM-1 NUPxdGJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjTd5FIUUN3ME2wMlkxOTVizszN NUToR44yW0GQR1XS
LB2241-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3tNJBKSzVyPUGuNFIzOjhizszN M1yzfHNCVkeHUh?=
NCI-H1703 M2rKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHJTWM2OD1zLkG4PFch|ryP NV3HS21PW0GQR1XS
BE-13 M{KzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILTV2tKSzVyPUGuNlc1OTZizszN MoPaV2FPT0WU
ACN Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwNUWwO|ch|ryP MmSxV2FPT0WU
A204 NHmy[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXruSIp[UUN3ME2xMlU4OjB3IN88US=> M1XVfXNCVkeHUh?=
HOP-62 M4TS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwOEKwO|ch|ryP MVfTRW5ITVJ?
H9 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPCTWM2OD1{LkezO|k{KM7:TR?= MkW0V2FPT0WU
HCC1806 M2fIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXThN3hVUUN3ME2yMlc1OzJ5IN88US=> M2nCNHNCVkeHUh?=
NOS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjKVXVjUUN3ME2yMlg4OTB{IN88US=> NF62SIpUSU6JRWK=
RS4-11 NFfxPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwOUC2NlMh|ryP NEjqNHJUSU6JRWK=
JAR MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3myVmlEPTB;Mj65NlA5PCEQvF2= MXvTRW5ITVJ?
T98G NF71T|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDzVFVKSzVyPUOuNFE{OTNizszN MUTTRW5ITVJ?
NCI-SNU-1 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLiUJp5UUN3ME2zMlQxODl{IN88US=> MVzTRW5ITVJ?
SK-MEL-1 NWLUR4dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjxSI4{UUN3ME2zMlQ{ODJ7IN88US=> M1TqR3NCVkeHUh?=
L-363 NFLiZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nFS2lEPTB;Mz62NVExPyEQvF2= NIjBTY1USU6JRWK=
SW982 M3ywRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;JTINKSzVyPUOuOlQyPjlizszN MWPTRW5ITVJ?
HT-1080 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rZeGlEPTB;Mz65NVc4PSEQvF2= NU\XTW9nW0GQR1XS
G-402 NYPmWG1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzRTWM2OD12LkOxNlA{KM7:TR?= MkTjV2FPT0WU
HOS NF;4NmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fhNmlEPTB;ND64NFI5OiEQvF2= NWTndohjW0GQR1XS
SK-NEP-1 NHLDfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr4OJJKSzVyPUSuPFMyQTFizszN M1fLWHNCVkeHUh?=
HAL-01 M3f5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTRwOEiyOFIh|ryP NWjIeFl3W0GQR1XS
SBC-1 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTRwOUC5NFch|ryP NHnwUm1USU6JRWK=
CTV-1 NHOxe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTVwNEi5N|gh|ryP NWD1fppQW0GQR1XS
LCLC-103H NEfvXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwN{e0O|Eh|ryP NYr3[nptW0GQR1XS
RVH-421 NXL1PVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;nOpFKSzVyPUWuO|c2OzZizszN MmXkV2FPT0WU
K-562 M4KwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjMTWM2OD13LkmwN|Yh|ryP M1PCOXNCVkeHUh?=
CAL-33 NFjheGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf3TWM2OD14LkOxN|U6KM7:TR?= NXLMbGxRW0GQR1XS
MDA-MB-361 M4\yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXqZZVKSzVyPU[uN|M3QTlizszN NHX4OXZUSU6JRWK=
IGROV-1 NHfGdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCzUoRkUUN3ME22MlQ4OTlzIN88US=> MnL1V2FPT0WU
NY NXTPZVhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfkXVBCUUN3ME22MlU{PTl7IN88US=> NFS2e2RUSU6JRWK=
Ramos-2G6-4C10 M4TvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TCU2lEPTB;Nj62Olk{OSEQvF2= M3L2ZXNCVkeHUh?=
HuO9 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS4TWM2OD14LkezPVY1KM7:TR?= MV7TRW5ITVJ?
MS-1 M1i0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInSenZKSzVyPUeuNVE6PTNizszN NViyZVNDW0GQR1XS
RPMI-8226 NX[2O4l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXZNJhXUUN3ME23MlI5Ojh5IN88US=> NIG3Z|JUSU6JRWK=
HDLM-2 NFvubFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm0PGRKSzVyPUeuOFAyPDlizszN Moi3V2FPT0WU
D-566MG M1HTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTdwNEexOVUh|ryP MlHsV2FPT0WU
SK-MEL-24 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjBdWZ3UUN3ME23MlY{Ozl{IN88US=> M{\k[HNCVkeHUh?=
COLO-679 NEDDW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjsTWM2OD15Lkm4OlcyKM7:TR?= M33SR3NCVkeHUh?=
EW-13 Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z6O2lEPTB;OD6zNlA2PCEQvF2= M1nQ[XNCVkeHUh?=
A388 M1j1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDtTZpKSzVyPUiuN|g1QDFizszN MXPTRW5ITVJ?
UM-UC-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq2TWM2OD16LkSzPVU3KM7:TR?= MYHTRW5ITVJ?
NUGC-3 NIf4T3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2dXZKSzVyPUiuOVM2QDJizszN NYHkbVNRW0GQR1XS
COLO-668 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DWbWlEPTB;OD61PVQ6OSEQvF2= MXfTRW5ITVJ?
MOLT-4 M2joSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zIc2lEPTB;OD62NlM2OyEQvF2= NHq1[XRUSU6JRWK=
D-423MG NU\pc4hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DWRWlEPTB;OD64N|c2PiEQvF2= M2[ycnNCVkeHUh?=
CTB-1 NWXTT2hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n3T2lEPTB;OD64O|EzQCEQvF2= NUTMbWRZW0GQR1XS
BCPAP NFjHXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXHeZRSUUN3ME25MlAzPTZ{IN88US=> NV\QS|BuW0GQR1XS
GCT NUP4[IJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXnTWM2OD17LkC5PFMyKM7:TR?= M1vRPXNCVkeHUh?=
ACHN M{PYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTlwMkO2N|Ih|ryP NE\GeVVUSU6JRWK=
KYSE-520 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTlwM{O0PFIh|ryP MnG0V2FPT0WU
LB771-HNC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTlwN{[0PVch|ryP MXzTRW5ITVJ?
MLMA MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrsTWM2OD1zMD6wNVMzKM7:TR?= NFTXeoVUSU6JRWK=
HEC-1 NUjXVJZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfPdplKSzVyPUGwMlI5ODRizszN MlqxV2FPT0WU
HL-60 NYXBfIlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XMRmlEPTB;MUCuOlg2OyEQvF2= M1vpUHNCVkeHUh?=
A101D NFfrc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3rfmhKSzVyPUGwMlg6OjNizszN NV\jOHlsW0GQR1XS
A2058 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvNTWM2OD1zMD65NlQ2KM7:TR?= NEjhemVUSU6JRWK=
KARPAS-45 Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDoTWM2OD1zMT6wOlM2KM7:TR?= MnHhV2FPT0WU
697 M17x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL0TWM2OD1zMT6yNVAyKM7:TR?= M3;hcXNCVkeHUh?=
NCI-N87 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr2TWM2OD1zMT63O|MyKM7:TR?= NXHVe|lpW0GQR1XS
DSH1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XZOmlEPTB;MUGuO|k2OyEQvF2= NFHyfmlUSU6JRWK=
HLE MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSzTWM2OD1zMT64PFM6KM7:TR?= M{fDfXNCVkeHUh?=
NCI-H720 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrOTW92UUN3ME2xNk43QDBzIN88US=> MorwV2FPT0WU
EW-3 NEfNZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnOd|B4UUN3ME2xNk46OzB5IN88US=> NGHXWnpUSU6JRWK=
AGS Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fnVmlEPTB;MUOuNFM2OSEQvF2= NYXwVWdHW0GQR1XS
ES5 NXG4[YJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojBTWM2OD1zMz6wOVEzKM7:TR?= Mn25V2FPT0WU
DB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTF|LkOyOVYh|ryP MmD0V2FPT0WU
A4-Fuk NIjTS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF|LkSxNFIh|ryP M3vWTnNCVkeHUh?=
A427 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF|LkS5O|Ih|ryP NE\FW5BUSU6JRWK=
MN-60 M3Pp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPqTWM2OD1zMz61PFQ{KM7:TR?= NX\BS|hQW0GQR1XS
HCC2218 NUmz[5FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLSXmlQUUN3ME2xN{42QDV4IN88US=> MWfTRW5ITVJ?
MV-4-11 NVz2RlJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF|LkixN|ch|ryP NIDZVJpUSU6JRWK=
GI-1 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF2LkGxPFQh|ryP M33RenNCVkeHUh?=
JVM-3 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF2LkK2OVYh|ryP M1HINXNCVkeHUh?=
NCI-H2029 NH3CW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonoTWM2OD1zND6yO|I4KM7:TR?= M2HJdXNCVkeHUh?=
TE-12 M3y1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF2Lk[wOFYh|ryP NUG5R3hlW0GQR1XS
WM-115 NH24R4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF3LkW2PFMh|ryP MWLTRW5ITVJ?
BB65-RCC M4rzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH4T5RTUUN3ME2xOk4xOjRzIN88US=> M3nCcHNCVkeHUh?=
NCI-H1693 NHPpd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HVVmlEPTB;MU[uN|gxOiEQvF2= MmrCV2FPT0WU
KARPAS-299 NUPwNm55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF4Lk[yNFMh|ryP M2[xcXNCVkeHUh?=
UACC-257 NVHXOFFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHFTWM2OD1zNz6wOVgzKM7:TR?= NXPBeINoW0GQR1XS
RKO NXPMU5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj5dllWUUN3ME2xO{43PDN|IN88US=> NEnCbXZUSU6JRWK=
HT-29 NI\I[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF5Lke4PFkh|ryP Mn\hV2FPT0WU
ES7 M4C4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\oZYdKSzVyPUG4MlEyOjJizszN NXO4eXA3W0GQR1XS
DEL NUmzZ|lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fue2lEPTB;MUiuN|E4OiEQvF2= NY[1c25zW0GQR1XS
BT-549 M4LnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjuR2RlUUN3ME2xPE41ODl{IN88US=> MYDTRW5ITVJ?
NCI-H1755 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF6LkW3NlMh|ryP Ml22V2FPT0WU
HCE-T NYrYWIl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTKTWM2OD1zOD64N|QyKM7:TR?= NX7GcFl2W0GQR1XS
LU-139 NW\Oc5l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfKfW1KSzVyPUG5MlA1PThizszN M371WXNCVkeHUh?=
ECC10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xq[2lEPTB;MUmuNlQ4PSEQvF2= MYTTRW5ITVJ?
769-P NWHlVZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MleyTWM2OD1zOT62N|M2KM7:TR?= NF3OUmZUSU6JRWK=
BALL-1 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULPNVVzUUN3ME2xPU43Pzd3IN88US=> MWfTRW5ITVJ?
LXF-289 M{\We2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCyTWM2OD1zOT64PVc6KM7:TR?= NVrmTXpIW0GQR1XS
TYK-nu M2\pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf4T3VKSzVyPUG5Mlk{OTVizszN NGDBZWRUSU6JRWK=
NCI-H630 NWHPdoI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HmPWlEPTB;MUmuPVM4QCEQvF2= MUTTRW5ITVJ?
EW-18 NWXqN2Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzuZZZ2UUN3ME2yNE4{QDB{IN88US=> NXnQWJMyW0GQR1XS
KYSE-150 NYjySoZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXUTWM2OD1{MD63NFQ4KM7:TR?= M1zi[3NCVkeHUh?=
LOXIMVI M4fkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm0OnVKSzVyPUKwMlc2QDZizszN MV7TRW5ITVJ?
HuP-T3 NX7wOVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jDd2lEPTB;MkGuNFg2OiEQvF2= MonTV2FPT0WU
MFE-280 NFjufHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmyNo1jUUN3ME2yNU42Pjd7IN88US=> M1Lvb3NCVkeHUh?=
SK-OV-3 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTWTWM2OD1{MT64OFA5KM7:TR?= NYDHW4w{W0GQR1XS
QIMR-WIL M33xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTUN3E3UUN3ME2yNk4xPDd6IN88US=> M1PNdXNCVkeHUh?=
NCI-H69 NW\lenVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPYWVRKSzVyPUKyMlQzQTlizszN MYPTRW5ITVJ?
TE-5 NGHSXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXib2xKSzVyPUKyMlQ6PjVizszN M3npRnNCVkeHUh?=
NCI-H1993 NF\OVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7kTWM2OD1{Mj60PVcyKM7:TR?= MojKV2FPT0WU
NCI-H1092 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XjNWlEPTB;MkOuNlg1OyEQvF2= MmnNV2FPT0WU
RH-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ|LkWzOVch|ryP M{jMV3NCVkeHUh?=
DBTRG-05MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ|Lki0O|Ih|ryP M1jWd3NCVkeHUh?=
Mo-T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ|Lkmg{txO M2PtPHNCVkeHUh?=
HD-MY-Z MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfkTWM2OD1{ND6yN|YzKM7:TR?= NUnz[5hUW0GQR1XS
NCI-H2342 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLpTWM2OD1{ND62O|Y4KM7:TR?= MlzHV2FPT0WU
C32 NV\ReWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7iWGxvUUN3ME2yOE46PTd4IN88US=> M1ToS3NCVkeHUh?=
HTC-C3 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ3LkO1O|ch|ryP NVzPTphLW0GQR1XS
NCI-H358 NV3pPHBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ3LkO5OFMh|ryP NVLzclNCW0GQR1XS
CAL-85-1 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjtTWM2OD1{NT60OVc4KM7:TR?= MWrTRW5ITVJ?
HT-1197 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ3LkWzNVkh|ryP MorFV2FPT0WU
A172 NHjIT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDLcHdKSzVyPUK1MlcyOzZizszN MXTTRW5ITVJ?
SW1573 M{XSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrU[FhXUUN3ME2yOU44Pzh3IN88US=> MoHkV2FPT0WU
EW-24 NGX0eXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC2TWM2OD1{NT65OlIh|ryP MVLTRW5ITVJ?
SK-MEL-2 M1;GSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrGOIhKSzVyPUK2MlA{OTJizszN NH\ycnNUSU6JRWK=
LU-65 NWiyUmMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;5V2lEPTB;Mk[uNFQ2OiEQvF2= NHv0NoNUSU6JRWK=
KMOE-2 NV;XcHg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzOTWM2OD1{Nj6wPVE2KM7:TR?= NHLVdIdUSU6JRWK=
H-EMC-SS NXS2RYwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOzN3dKSzVyPUK2MlQyOTRizszN NFXITmJUSU6JRWK=
H4 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH6NGVrUUN3ME2yOk41OjR|IN88US=> NUOwZ5lnW0GQR1XS
DU-4475 NU\5fWtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzFTWM2OD1{Nz6xPFczKM7:TR?= M3\EcnNCVkeHUh?=
HCT-116 M32xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjDZpVGUUN3ME2yO{41OzR7IN88US=> M{HidHNCVkeHUh?=
MSTO-211H MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD0fGk3UUN3ME2yO{43OjV3IN88US=> MmTIV2FPT0WU
NCI-H292 M2TyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HUdmlEPTB;MkeuPVYyPyEQvF2= M3fme3NCVkeHUh?=
NCI-H446 NVzMeoF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJ6LkKxNFUh|ryP M1nqfXNCVkeHUh?=
NCI-H2009 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ7LkG0N|Eh|ryP NYO5WYtGW0GQR1XS
MHH-ES-1 MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16zT2lEPTB;MkmuN|Y5PSEQvF2= M1jjWXNCVkeHUh?=
TI-73 M3ztTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxSmlEPTB;MkmuOFAxOSEQvF2= MkXPV2FPT0WU
NCI-H2228 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nI[2lEPTB;MkmuOFU5KM7:TR?= Ml;XV2FPT0WU
MHH-PREB-1 NWLoc211T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ7LkW1NFUh|ryP NEXCOWdUSU6JRWK=
ChaGo-K-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLJR4E4UUN3ME2yPU43ODl5IN88US=> NXXwOXV7W0GQR1XS
KY821 M2Pp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ7Lk[0N|Mh|ryP MWPTRW5ITVJ?
NCI-H209 NF:3eYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jPUmlEPTB;MkmuPFM3PiEQvF2= M4DIRnNCVkeHUh?=
NBsusSR MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L0VGlEPTB;MkmuPVkxPCEQvF2= MX7TRW5ITVJ?
NCI-H1304 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3TZWJ3UUN3ME2zNE42PzF4IN88US=> MkWwV2FPT0WU
NB14 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNzLkC0OFYh|ryP NWfUfo1MW0GQR1XS
HCC1419 NELy[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vvS2lEPTB;M{GuNlQh|ryP M3LTT3NCVkeHUh?=
KG-1 M3PmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPoRYd4UUN3ME2zNU44PDJ7IN88US=> MWLTRW5ITVJ?
A2780 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNzLkizOVgh|ryP NIrkZXVUSU6JRWK=
NCI-H28 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjSPHIyUUN3ME2zNU46QDZzIN88US=> NUDnU29bW0GQR1XS
C2BBe1 NEXLTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\aemdHUUN3ME2zNk4zPjN2IN88US=> NHz6UXVUSU6JRWK=
VA-ES-BJ NY\KPHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTN{LkOxJO69VQ>? M1nWZXNCVkeHUh?=
SBC-5 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[3c|hrUUN3ME2zNk45PTFzIN88US=> NGrLSWVUSU6JRWK=
OVCAR-4 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HPZWlEPTB;M{OuOFg1QCEQvF2= NVj1PHBnW0GQR1XS
COR-L88 M2PmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrVTWM2OD1|ND6wO|QyKM7:TR?= M2fXWnNCVkeHUh?=
SW954 M4\wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G5UGlEPTB;M{SuNFc2OiEQvF2= MkfuV2FPT0WU
COLO-684 MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W2TWlEPTB;M{SuN|QxPCEQvF2= M2D6OnNCVkeHUh?=
HCC70 NFLoUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjB[25mUUN3ME2zOE46PTF2IN88US=> MoTlV2FPT0WU
NCI-H1770 NX3Q[XA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjV2FRUUN3ME2zOE46PjFizszN NIL0[pdUSU6JRWK=
NCI-H1666 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LETGlEPTB;M{WuPFI2OyEQvF2= M4rsNHNCVkeHUh?=
YH-13 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32zdGlEPTB;M{WuPVIh|ryP M2DDd3NCVkeHUh?=
DJM-1 M1LrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTN4LkiwOFkh|ryP NYLaN|VGW0GQR1XS
KNS-62 Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLrTWM2OD1|Nj65OFM5KM7:TR?= MWfTRW5ITVJ?
SK-MEL-30 NYjHb4tjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;uNWlEPTB;M{euPFc{PyEQvF2= MYjTRW5ITVJ?
SJRH30 M2T3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW2TWM2OD1|OD63N|QyKM7:TR?= MoTCV2FPT0WU
GP5d NF7wUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfQTWM2OD1|OD64OlU{KM7:TR?= NWj1bo1qW0GQR1XS
SW1116 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkizTWM2OD1|OT6yPFA2KM7:TR?= M4\jTXNCVkeHUh?=
COLO-800 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDFdGhpUUN3ME2zPU4{PjN6IN88US=> MYLTRW5ITVJ?
RD NX\yfYJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe5[XNKSzVyPUO5MlUzPThizszN NFPv[HJUSU6JRWK=
NCI-SNU-5 NF3LXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\nbG5ZUUN3ME2zPU43QTF4IN88US=> MY\TRW5ITVJ?
HuO-3N1 NELRfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTRyLkGwPEDPxE1? NVHXOGZQW0GQR1XS
SK-UT-1 NX:yW4l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHqwNpRKSzVyPUSwMlU3PzRizszN NVX4eFRuW0GQR1XS
SK-MEL-3 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzQdpVKSzVyPUSwMlU6OzJizszN M1HRUHNCVkeHUh?=
SK-MEL-28 NID3c3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRyLk[0N|Uh|ryP Ml3oV2FPT0WU
SCC-4 NYi0RplrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DXO2lEPTB;NEGuNlE{PyEQvF2= MnvSV2FPT0WU
no-11 M4DsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX1bItKSzVyPUSxMlc{PTRizszN MVPTRW5ITVJ?
HT-144 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljITWM2OD12Mj6wOVY4KM7:TR?= NW\u[IhvW0GQR1XS
MFM-223 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTR{LkSwNkDPxE1? M2rjNHNCVkeHUh?=
ONS-76 M4nUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTR{LkiwNVgh|ryP MV;TRW5ITVJ?
ES8 NFTpd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;pTWM2OD12Mz6zOlk5KM7:TR?= M{fRfnNCVkeHUh?=
T-24 NIOzbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;aVWlEPTB;NEOuOFM3QSEQvF2= NYm1enk1W0GQR1XS
GAMG NHzZ[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjvfXJKSzVyPUSzMlQ2OTdizszN M2D1PHNCVkeHUh?=
LU-135 NFXSZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTR2LkC5NlMh|ryP MnmyV2FPT0WU
HCC1187 NUK1RoVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHLUIFKSzVyPUS0MlgzPjJizszN NF7VcGVUSU6JRWK=
TE-1 M1:3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR3LkG2OVQh|ryP NV\3dGRFW0GQR1XS
J-RT3-T3-5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDSR|ZKSzVyPUS1MlQ{OTVizszN MmrLV2FPT0WU
GI-ME-N NULjcZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\4TWM2OD12NT64PVUzKM7:TR?= Mn:wV2FPT0WU
D-392MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[2TmlEPTB;NEWuPVI2PiEQvF2= NIDCUIFUSU6JRWK=
KALS-1 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTR4LkeyOVch|ryP M3XwXXNCVkeHUh?=
MMAC-SF NILmcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;DSpI6UUN3ME20Ok46QTV{IN88US=> MX3TRW5ITVJ?
HSC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfjWm1KSzVyPUS3MlM3ODhizszN M{fkeHNCVkeHUh?=
KM-H2 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnGTWM2OD12Nz62NFA4KM7:TR?= Ml\zV2FPT0WU
LoVo M{fENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvVem1iUUN3ME20PE4yODB{IN88US=> NH7XV|NUSU6JRWK=
NCI-H510A NWP0ToZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W2TmlEPTB;NEiuNVg4OSEQvF2= M4fyTnNCVkeHUh?=
EW-11 M2DO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTR6LkKzOFgh|ryP NHrIeHRUSU6JRWK=
HCC2998 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR6Lk[yN|Yh|ryP MlXQV2FPT0WU
J82 NXrSUlNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fWZmlEPTB;NEiuO|I1OiEQvF2= M3zzZXNCVkeHUh?=
ML-2 NXTPZ3c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTR7LkS2NFUh|ryP MYHTRW5ITVJ?
NCI-H2030 NVzwWId{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nhTmlEPTB;NEmuO|EyPyEQvF2= Mn:yV2FPT0WU
NCI-H1792 M1fjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTR7Lki1NVgh|ryP MUHTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-AMPKα / AMPKα / p-AMPKβ1 / AMPKγ2 / p-LKB1 / LKB1 / CaMKIIβ ; 

PubMed: 23677989     


Dose-dependent analysis of AMPK-related molecules in HCC cells. Cells were exposed to nilotinib at the indicated concentrations for 24 h.

DNMT1 / DNMT3a / DNMT3b ; 

PubMed: 28720666     


Kasumi-1 or MV4-11 cells were treated for 24 h with the indicated doses of nilotinib and subjected western blot analysis to detect the expression levels of DNMT1, DNMT3a, DNMT3b.

pABL1 / p-NF-κB1 / NF-κB / STAT3 / p-STAT3 / IL-1β / IL-6 / COX2 ; 

PubMed: 31396300     


ABL1 regulated the inflammation signaling pathway. Blocking activities of ABL1 with Imatinib and Nilotinib inhibits the inflammatory signaling pathway including activities of NF-κB1, STAT3, IL-1β, IL-6, and COX2.

23677989 28720666 31396300
Growth inhibition assay
Cell viability; 

PubMed: 23677989     


Dose-dependent effects of nilotinib on cell viability. HCC cells were treated with nilotinib at the indicated concentrations for 72 h. Cell viability was measured by MTT assay. Points, mean; bars, S.D. (n = 8). 

23677989
体内試験 Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

お薦めの試験操作(参考用のみ)

細胞試験: [4]
- 合併
  • 細胞株: Human primary Schwann and schwannoma cells
  • 濃度: 1-10 μM
  • 反応時間: 72 hours
  • 実験の流れ: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (参考用のみ)
動物試験:[6]
- 合併
  • 動物モデル: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • 投薬量: 75 mg/kg, 100 mg/kg
  • 投与方法: Oral administration
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 529.52
化学式

C28H22F3N7O

CAS No. 641571-10-0
Storage powder
in solvent
別名 N/A
Smiles CC1=C[N](C=N1)C2=CC(=CC(=C2)C(F)(F)F)NC(=O)C3=CC=C(C)C(=C3)NC4=NC=CC(=N4)C5=CN=CC=C5

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04326933 Not yet recruiting Drug: Tyrosine kinase Inhibitors (Imatinib & Nilotinib) Patients Diagnosed as Chronic Meyloid Leukemia Assiut University October 20 2020 --
NCT03942094 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Chronic Phase|Nilotinib Shenzhen Second People''s Hospital June 1 2019 Phase 3
NCT03874858 Recruiting Drug: Nilotinib Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 1 2019 Phase 2
NCT04002674 Active not recruiting Drug: Placebo oral capsule|Drug: Nilotinib Oral Capsule Dementia With Lewy Bodies Georgetown University|National Institutes of Health (NIH) January 14 2019 Phase 2
NCT02973711 Suspended Drug: Nilotinib|Drug: Ruxolitinib Leukemia Chronic Myeloid University of Michigan Rogel Cancer Center January 18 2018 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • 回答:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Ablシグナル伝達経路

Bcr-Abl Inhibitors with Unique Features

相関Bcr-Abl製品

Tags: Nilotinib (AMN-107)を買う | Nilotinib (AMN-107) ic50 | Nilotinib (AMN-107)供給者 | Nilotinib (AMN-107)を購入する | Nilotinib (AMN-107)費用 | Nilotinib (AMN-107)生産者 | オーダーNilotinib (AMN-107) | Nilotinib (AMN-107)化学構造 | Nilotinib (AMN-107)分子量 | Nilotinib (AMN-107)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID